Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Sold by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP reduced its position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 71.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 101,558 shares of the company’s stock after selling 256,896 shares during the period. Advantage Alpha Capital Partners LP’s holdings in Organogenesis were worth $290,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Assenagon Asset Management S.A. boosted its position in Organogenesis by 309.3% during the second quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company’s stock worth $11,136,000 after purchasing an additional 3,005,450 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Organogenesis by 76.9% during the 2nd quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock worth $6,353,000 after buying an additional 986,132 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Organogenesis by 19.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock valued at $5,702,000 after buying an additional 333,123 shares in the last quarter. Wealth Dimensions Group Ltd. grew its stake in Organogenesis by 435.9% in the 2nd quarter. Wealth Dimensions Group Ltd. now owns 407,965 shares of the company’s stock valued at $1,142,000 after acquiring an additional 331,840 shares during the period. Finally, Jacobs Levy Equity Management Inc. increased its holdings in Organogenesis by 349.1% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 186,236 shares of the company’s stock worth $529,000 after acquiring an additional 144,771 shares in the last quarter. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Organogenesis Stock Down 2.0 %

NASDAQ:ORGO opened at $3.96 on Wednesday. The company has a fifty day moving average of $3.21 and a two-hundred day moving average of $2.91. Organogenesis Holdings Inc. has a fifty-two week low of $2.16 and a fifty-two week high of $4.70. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. The firm had revenue of $115.18 million for the quarter, compared to analyst estimates of $109.59 million. During the same period last year, the company posted $0.02 EPS. On average, equities research analysts forecast that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.